MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Alkermes PLC

Cerrado

SectorSanidad

32.65 0.46

Resumen

Variación precio

24h

Actual

Mínimo

32

Máximo

32.77

Métricas clave

By Trading Economics

Ingresos

54M

147M

Ventas

52M

430M

P/B

Media del Sector

15.078

63.778

BPA

1.05

Margen de beneficios

34.072

Empleados

1,800

EBITDA

58M

181M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+20.32% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

298M

5.4B

Apertura anterior

32.19

Cierre anterior

32.65

Noticias sobre sentimiento de mercado

By Acuity

36%

64%

129 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Alkermes PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 23:55 UTC

Acciones populares

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 abr 2025, 22:50 UTC

Principales Movimientos del Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 abr 2025, 21:08 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 abr 2025, 21:00 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 abr 2025, 23:56 UTC

Charlas de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 abr 2025, 23:44 UTC

Principales Noticias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 abr 2025, 23:32 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 23:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 23:32 UTC

Charlas de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 abr 2025, 23:10 UTC

Charlas de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:57 UTC

Charlas de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 abr 2025, 22:56 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:56 UTC

Charlas de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 abr 2025, 22:43 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 abr 2025, 22:12 UTC

Charlas de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 abr 2025, 21:48 UTC

Principales Noticias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 abr 2025, 21:41 UTC

Charlas de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 21:17 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 abr 2025, 21:04 UTC

Principales Noticias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 abr 2025, 21:03 UTC

Charlas de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 abr 2025, 20:53 UTC

Ganancias

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 abr 2025, 20:52 UTC

Ganancias

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparación entre iguales

Cambio de precio

Alkermes PLC previsión

Precio Objetivo

By TipRanks

20.32% repunte

Estimación a 12 Meses

Media 39.14 USD  20.32%

Máximo 52 USD

Mínimo 30 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

8

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

32.05 / 33.7Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

129 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.